Skip to content

Metformin and Congenital Nephrogenic Diabetes Insipidus

Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02460354
Enrollment
2
Registered
2015-06-02
Start date
2015-09-30
Completion date
2017-06-30
Last updated
2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Insipidus

Keywords

Congenital nephrogenic diabetes insipidus

Brief summary

The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).

Detailed description

Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don't hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don't drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less.

Interventions

DRUGMetformin

Metformin 500 mg pill dispensed once orally

Sponsors

Emory University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males with a documented mutation in the vasopressin type 2 receptor (V2R) * Willing to provide consent and/or assent as appropriate * Capable of providing urine samples as dictated by the protocol

Exclusion criteria

* Urinary incontinence * Subjects who have heart disease, liver disease, diabetes, cancer, or other significant disease other than Nephrogenic Diabetes Insipidus (NDI) * Subjects with significant renal dysfunction (defined as a calculated glomerular filtration rate (GFR) \<80 ml/min/1.73 m\^2) * Subjects with acquired NDI

Design outcomes

Primary

MeasureTime frameDescription
Change in mean urine osmolalityBaseline, 7 hoursUrine osmolality is a measure of urine concentration. Urine osmolality will be measured using a Wescor vapor pressure osmometer. A normal range for urine osmolality is approximately 500-850 mOsm/kg water. Change is the difference in average osmolality from baseline to 7 hours.

Secondary

MeasureTime frameDescription
Change in mean urine volumeBaseline, 7 hoursUrine volume is a measure of fluid balance. Change from baseline in average volume of urine collected from baseline to 7 hours.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026